Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements

Reuters09-16

<a href="https://laohu8.com/S/EOLS">Evolus Inc.</a> Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements

Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau® brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&D and launched its first two products, Hemotese® and Collapat®II. The presentation also notes a strengthened R&D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2567141656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 02:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567141656","market":"nz","top_or_hot":-1,"title":"Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EOLS\">Evolus Inc.</a> Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau® brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&amp;D and launched its first two products, Hemotese® and Collapat®II. The presentation also notes a strengthened R&amp;D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-16 02:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EOLS\">Evolus Inc.</a> Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau® brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&amp;D and launched its first two products, Hemotese® and Collapat®II. The presentation also notes a strengthened R&amp;D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL5tFvH1:1","article_id":"2567141656","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567141656","pubTimestamp":1757960878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements. Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&D and launched its first two products, Hemotese and CollapatII. The presentation also notes a strengthened R&D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.Disclaimer: This news brief was ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EOLS":"Evolus Inc."},"translate_title":"Evolus Inc.推出科学投资者演示文稿，重点介绍创新美学技术和临床进步","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":0.9},"content_text":"Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements\n    \n\n        Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau® brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&D and launched its first two products, Hemotese® and Collapat®II. The presentation also notes a strengthened R&D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567141656","isCrawlerRequest":true}